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Background: Hepatitis C virus is a persistent epidemiological problem, with an estimated 170 million individuals
infected worldwide, and the leading cause of asymptomatic chronic infection, liver cirrhosis and hepatocellular
carcinoma. Injection drug users (IDUs) have the highest seroprevalence as compared to chronic hemodialysis and
transfusion patients, and this cohort remains the most under-studied high-risk group in North Africa to date. This
study first sought to characterize the demographic, epidemiological, and genotypic profile of a total sample size of
211 chronically-infected IDUs living in the Tangier region of Northern Morocco, and secondly to contrast this to
other chronically-infected patients, in order to uncover possible discrepancies.
Results: The general ‘profile’ of local IDUs marks a stark contrast to chronically-infected HCV Moroccan patients,
other African countries, and neighboring European countries. The majority of Moroccan drug users were found to
be middle-aged and celibate. A relatively high seroprevalence was found among drug users (60%), and this increased
with age. The majority of drug users shared their needles and this hold implications for transmission, as seropositive
status was significantly different between those users that shared vs. those that did not share their needles. In addition,
IDUs exhibited genotypes 1a and 3a predominantly, as compared to the predominant 1b and 2a/2c genotypes found
in chronically HCV-infected patients. The IDU genotypic profile closely matches the one in other European countries
(Portugal, Spain, France, and Italy), which are invariably speculated as the potential source of currently-circulating
genotypes in Moroccan IDUs.
Conclusion: These findings have implications for disease prevention, transmission and treatment, as this distinct IDU
subgroup cannot be collectively pooled along with other HCV-positive high-risk groups. Local government, practitioners,
and health institutions should take this into account when treating, prescribing antiviral therapy, and designing
preventative public health campaigns.
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Since its discovery in the 1980s, Hepatitis C Virus (HCV)
has caused significant mortality and morbidity with an es-
timated 170 million people infected worldwide (Aitken
et al.) [1]. Even though this blood-borne virus has received
less spotlight than other infectious virus counterparts such
as HIV-1, it has infected nearly four times as many people
and is expected to overtake the number of death resulting* Correspondence: abdelouaheb.bennani@pasteur.ma
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unless otherwise stated.from liver-related damage and hepatocellular carcinoma
(HCC) as by AIDS (Cohen) [2]. Only 25% of infected indi-
viduals will clear the virus within the first 6 months, and
thus, this low clearance translates into most infected indi-
viduals becoming chronic carriers. The acute infection
phase is mostly asymptomatic or with mild non-specific
symptoms such as lethargy and myalgia, result in that
many cases remain undetected for years (Grebley et al.)
[3]. Modern day combination triple therapy used to treat
HCV infection is composed of pegylated interferon-alpha,
ribavirin and direct acting antivirals, the cost of which
averages around US$1,100 per week and comes with its
fair share of side effects (Mole) [4]. Furthermore, the
virus’ high mutation rate, rapid evolution and high genetical Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment and collectively has resulted in no marketed vaccine
to date (Liang) [5].
The Arab world is a very large and vast region, encom-
passing the Arabian Peninsula, Sham region, Arabian Nile
region, and the North African region, is no exception to
this epidemic and is estimated to harbour 25 million in-
fected individuals and an average prevalence rate of 3.5%.
Illegal drug use along with sexual activity outside of wed-
lock fall into the boat of taboo topics resulting in that in-
vestigators having shunned this research area until recent
years (Daw & Dau) [6]. Further complicating the matter is
the low level of government funding for epidemiological
research activities, ultimately resulting in an unconfirmed
true prevalence rate for most countries in this region.
Of all the countries in the world, Egypt has the highest
prevalence of HCV estimated at 14.7% (Mohamoud et al.)
[7], which has been ravaging the country for decades and is
thought to be mainly spreading through iatrogenic trans-
mission (Miller) [8]. Closer to home, the overall prevalence
of HCV in the general Moroccan population is lower and
classified as ‘intermediate’, currently estimated at 1.58%
and 1.93% (Baha et al.; Benouda et al.) [9,10]. We note a
discrepancy with the reported prevalence rate from the
previous decade, which was estimated to be 7.7% in pa-
tients hospitalized for various pathologies (Cacoub et al.)
[11]. We note that there might be a bias and that this dis-
crepancy in prevalence might be due to the fact that the
group of patients included the Cacoub study was a select-
ive and a more ill group and did not represent the general
Moroccan population.
The HCV situation is more contained in Morocco due
to the routine blood screening strategies implemented
20 years ago (Baha et al.) [9]. Presently, the major high-risk
groups in the country are hemodialysis and hemophiliac
patients, and injecting drug users. It is now globally ac-
cepted that the IDU cohort has the highest prevalence
among all the high-risk groups (ranging from 60-90%),
serves as a reservoir for the blood-borne virus, and ac-
counts for the overwhelming majority of new trans-
missions (Backmund et al.) [12]. This issue is further
aggravated by the fact that the majority of IDUs are
unaware of their seropositive status and do not routinely
seek treatment (Miller) [13]. Data on IDU seroprevalence
is only available in 7 countries in the Middle East (Cyprus,
Egypt, Iran, Israel, Lebanon, Saudi Arabia, and Syria), yet
the genotype distributions and complete profile for each
country are incomplete (Ramia et al.) [14].
No published data on the Moroccan IDU cohort exists
to date, despite the fact that there is extensive drug traf-
ficking on the Northern border between Spain. The sparse
and fragmentary nature of published data on the Maghreb
region (Morocco, Mauritania, Algeria, and Tunisia) has
resulted in a lack of thorough understanding and hindersthe planning of strategic long-term prevention strategies.
The primary aim of this study was to characterize the
somewhat ‘hidden’ IDU cohort of Morocco in terms of
their demographics, seroprevalence and genotype profile.
By targeting this high-risk group, tailored risk-management
and long-term preventative strategies can be developed and
implemented with the dual aim of lowering the HCV na-
tional prevalence rate and ultimately lessening the financial
and socio-economic burden of future generations.Results
Our study used a total sample size of 211 IDU patients, and
data collection on the various variables under study was
done over a 2-year period. General inclusion criteria into
the study cohort depended on the availability of a mini-
mum of one of the following relevant data variables: age/
year of birth; gender; marital status; needle-sharing habits
(Yes or No); route of drug administration; HCV seropositiv-
ity status (positive or negative); HCV genotype; HCV viral
load. Every effort was made to compile a complete data set
including data on all variables for each patients, however,
the difficulty involved in doing this resulted in the ‘condi-
tional inclusion’ of patients in a statistical test based on the
availability of the needed respective variables (pairwise dele-
tion). The data is assumed to be missing completely at ran-
dom, and subjects with missing observations for certain
measures were excluded from some tests, while included in
others. We sought to maximize the use of all available data
and in this way make use of a ‘rotating’ sub-sample taken
selectively from our total sample size. Analysis results are
presented along with the number of patients included in
each statistical test in question, and all p values inferior to
0.05 were considered significant.Demographic variables
The average age of IDUs was found to be 38.5 ± 8.7
(based on available year of birth data, n = 154), the median
was 40 years old, with an age range of 39 years (19 to
58 years old). Gender data was available for 167 subjects,
with the sex ratio of males to females was 148/19 = 7.78.
Civil status (n = 166 subjects): the majority of subjects
were single (119/166, 71.6%), while the remaining were
married (24/166, 14.5%), divorced (16/166, 9.6%), sepa-
rated (5/166, 3%), and widowed (2/166, 1.2%) respectively.
For HCV chronically infected subjects: the mean age of
patients was 59.8 ± 13.8 years (n = 151), and the median
60 years old. The youngest patient was 18 years old while
the oldest was 86 years old, yielding an age range of
68 years. The sex ratio of males to females was 51/100 =
0.51. No civil status data was available for chronic patients.
Average age of women (n = 100) was 59.7 ± 13.4 years and
the average age of men (n = 51) was 60.2 ± 14.7 years
respectively.
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The prevalence of HCV in our cohort was calculated
based on available viral load data obtained via RT-PCR,
where the patient was classified as positive if harbouring
a viral load higher than the limit of detection of 15 IU/mL.
The proportion of IDU patients seropositive for HCV was
89/148 = 0.60 (n =148). Age and seropositivity (n = 132
IDU subjects) were moderately correlated (R = 0.726, 95%
CI [0.633, 0.798]), as depicted in Figure 1. The average
viral load was calculated to be 2.66 × 106 ± 4.53 × 106 IU/mL
for IDUs (n = 49) and 2.79 × 106 ± 6.10 × 106 IU/mL for
chronically infected patients (n = 151). Independent sam-
ples t-test for the comparison of average viral load be-
tween IDUs and chronic patients, using the unequal
variance approach (F [1.813], p = 0.009) was non-significant
(t = 0.159, df = 109.46, p = 0.4369). Risk factors: Drug ad-
ministration route was assessed and revealed that a minor-
ity of drug addicts (8/101, 0.08%) smoke the heroine as
opposed to shooting it. Needle-sharing habits showed that
the overwhelming majority of IDUs shared their needles
(86/101 = 85.1%, n = 101). Chi-squared analysis for needle
sharing habits vs. seropositive status was significant (χ2 =
43.22, p = 4.87e-11).Figure 1 Title: positive correlation between age and average seropos
31-35; 36-40; 41-45; 46-50; 51-55) and average seropositivity was calculated pe
correlation between age and seropositivity (r = 0.726 95% CI [0.633, 0.798]). Se
specified on the X-axis. Individual data points are shown in circles, while avera
upon which the correlation is based is indicated in green.Genotype profiles
IDUs and chronically infected patients’ genotypic distri-
bution of HCV differs substantially. The majority of IDUs
(n = 74) carry genotype 1a (60.8%) and 3a (25.6%), with
a smaller number carrying genotypes 1b (4.05%) and 4
(9.4%) respectively, as seen in Table 1. The predomin-
ant genotypes exhibited by our IDUs matched closely
with several countries hugging the Mediterranean basin
(Table 2). Patients were grouped into 7 age intervals in
order to examine the relative genotype frequencies among
age groups, the results of which can be seen in Table 3.
Genotype 1a seems to be present in all ages, while geno-
type 3a seems to be present in younger IDUs and genotype
1b in older ones respectively. Genotype 4 remains infre-
quent, which closely approximates the general Moroccan
population. Chi-squared analysis of genotype profile com-
pared between IDUs and chronically infected patients was
significant (χ2 = 151.1, df = 5, p = 2.2e-16). ANOVA analysis
of viral load (IU/mL) as a response variable to genotype
was significant (F = 2.98, p = 0.0412, n = 49), indicating that
IDUs with genotype 1a had the highest viral load as com-
pared to all other genotypes (4.3 × 106 ± 5.5 × 106), as dis-
played in Figure 2.itivity. Legend: Subjects were binned into 7 age groups (21-25; 26-30;
r age group. Pearson’s Product Moment reveals a moderately positive
ropositivity (proportion) is specified on the Y-axis, while age groups are
ge seropositivity per age group is shown by the red line. Best-fit line
Table 1 HCV Genotype distribution among intravenous






Genotype 1a 45 60.8 6 5.2
Genotype 1b 3 4.05 45 39.1
Genotype 1nc 0 0 2 1.7
Genotype 2 0 0 44 38.2
Genotype 2nc 0 0 3 2.6
Genotype 3 19 25.6 9 7.8
Genotype 4 7 9.4 6 5.2
Genotype 5 0 0 0 0
Genotype 6 0 0 0 0
Total 74 100 115 100
Table 3 Distribution of HCV genotypes across various age
group
HCV genotype
Age (n) 1a 1b 3a 4a
16-20 (4) 1 (0.25) 0 3 (0.75) 0
21-25 (7) 5 (0.71) 0 1 (0.14) 1 (0.14)
26-30 (10) 6 (0.60) 0 3 (0.30) 1 (0.10)
31-35 (13) 7 (0.53) 1 (0.07) 1 (0.07) 4 (0.31)
36-40 (12) 7 (0.58) 2 (0.16) 3 (0.25) 0
41-45 (11) 8 (0.73) 3 (0.27) 0 0
46-50 (2) 2 (1.00) 0 0 0
IDU subjects (n = 59) were grouped into 7 age intervals, whereas number of
subjects per group are provided in brackets. The frequency counts of
genotypes observed is provided as well as the proportions in parentheses.
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While several published Moroccan studies exist in the
scientific literature on hemodialysis, haemophiliacs and
chronic HCV-infected patients (Sekkak et al.; Benouda
et al.; Benani et al.; Benjelloun et al.) [10,24-26], the IDU
group in the Maghreb region has remained a largely
under-studied cohort to date. Due to the paucity of pub-
lished data, this study sought to characterize this elusive
and high-risk group, as well as to elucidate key differ-
ence between it and other chronically HCV-infected pa-
tients in Morocco.
The average age of IDUs (n = 154) was found to be
38.5 ± 8.7 years and the median 40 years. The youngest
and oldest subjects were 19 and 58 years old respect-
ively, thereby our sample had an age range of 39 years.
Only a small fraction of subjects were reportedly in a
conjugal relationship (married, 14.5%), while the over-
whelming majority (85.5%) were either single, divorced,
widowed or separated. A large part of the subjects were
male, with a male/female sex ratio of 7.78 (n = 167). This
gender asymmetry may be explained in two ways: either
that the majority of the injecting drug users in Morocco areTable 2 Reported IDU genotype profile per country in
North Africa, Europe, and the Mediterranean basin
Country Genotype (%) Reference
Lebanon 3a (57%), 1a (21%), 4 (18%) Mahfoud et al. [15]
Greece 3a (59%), 1 (23%) Raptopoulou et al. [16]
Croatia 1b (61%), 3a (26%) Vince et al. [17]
Serbia 1b (41.4%), 3a (27.6%) Stamenkovic et al. [18]
Italy 1a (30%), 3a (40%), 1b (11%) Ciciarello et al. [19] ;
Stroffolini et al. [20]
France 1b (27%), 3a (21%), 1a (18%) Payan et al. [21]
Spain 1a (42.8%), 3a (20.6%) Alonso Alonso et al. [22];
Portugal 1a (64.9%), 3a (71.6%) Almeida Calado et al. [23]
Percentages of respective genotype are provided in brackets when available.indeed male and this is a predominantly male-associated
drug habit, or that females hesitated to report their addic-
tion because of social and cultural reasons.
In contrast, the chronically infected patients used as a
comparator population had an average age of 59.8 ±
13.8 years (n = 151), with a median of 60 years old, indicat-
ing that his cohort was somewhat older than the IDUs.
The age range was slightly larger as well (18 to 65 years,
range of 47 years), as we speculate this is due the fact that
there were older subjects present in the chronically in-
fected group. Another demographic difference observed
was the male to female sex ratio (51/100 = 0.51), as the
majority of the chronic carriers were women. This skew-
edness did not bias the mean age of all patients, as women
(n = 100) had an average age of 59.1 ± 13.4 years, and men
(n = 51) an average of 60.12 ± 14.7 years respectively.
Slightly more than half of our IDU cohort was found
to be anti-HCV positive (89/148, 60%), allowing us to
classify them into and confirm the ‘highly seroprevalent’
stigma associated with IDUs worldwide. Previously re-
ported studies in various parts of the world disclosed lower
HCV-positive proportions in their local IDUs: Lebanon
(50%) and Australia (45.8%) (Mahfoud et al.; Kynotch
Aitken et al.) [1,15], while other studies reported higher
HCV-positive proportions: San Francisco Bay Area, China,
and Greece at 80.2%, 66.7% and 73% respectively (Gigi;
Ucellini et al.; Bao & Liu) [27-29].
Age and seropositive status were shown to be positively
correlated (Baha et al.; Benouda et al.; Mathei et al.)
[9,10,30], in that older subjects (as a group) were more
likely to be seropositive as compared to younger subjects
(n =132). Due to our sufficient sub-sample size and wide
range of ages, we were able to repeat the analysis by bin-
ning our IDU cohort into 7 age groups and calculating the
average seropositivity for each group. Indeed, we report a
moderately positive correlation between age and average
seropositivity, confirming that the younger subjects were
less likely to be anti-HCV positive (R =0.726) (Figure 1).
Figure 2 Title: average viral load (IU/mL) per genotype (IDU). Legend: Plot of means of IDU genotype distribution depicting average viremia
(IU/mL) and standard deviations. No standard deviation given for genotype 1b as only one subject was available for assessment. Genotype: 1a
(n = 27, x ̅ = 4.3 x 106 ± 5.5 x 106 IU/mL); 1b (n = 1, x ̅ = 1.7 x 104 IU/mL); 3a (n = 16, x ̅ = 8.04 x 105 ± 1.3 x 106 IU/mL); 4a (n = 5, x ̅ = 2.8 x 106 ± 3.4 x
105 IU/mL). Genotype 1a shows the highest average viremia and standard deviation as compared to all other genotypes, however the highest
dispersion might be due to a large number of subjects in this catergory.
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anti-HCV blood-screening practice in 1994 (Baha et al.) [9],
and this is thought to have substantially contributed to the
reduction of new HCV transmissions among younger gen-
erations. In addition, we also believe that the younger IDUs
lower seropositivity can be explained by reduced duration
of exposure to the risk associated with injecting drug use.
Already identified and well-studied risk factors associ-
ated with HCV transmission are incarceration, tattooing,
needle-sharing, dental therapy, and a history of surgery
(Baha et al.; Rice et al.) [9,31]. In terms of route of drug
administration, only a small proportion (8/101 = 0.08%)
of IDUs reported smoking as their habitual route of drug
administration, as opposed to the more popular intra-
venous route. Five out of the eight users who smoked as
their primary method for taking the drug were found to
be anti-HCV positive, however, we note that the majority
of the IDUs who smoked heroine were not subsequently
screened for HCV-positive status. Further studies need to
be done in with a sufficiently large sample size in order to
establish route of drug administration as a bone fida risk
factor, one which has implications for risk of infection.
The other major risk factor our study sought to address
was the sharing of needles, with the majority of subjectsreportedly doing so (86/101, 85.15%). This habit reflects
the cultural aspect of the Moroccan and the larger Arab
society, in the sense that these collectivist cultures are
known for their sharing of food and goods as a symbol of
bonding, brotherhood, and hospitality. One might also
speculate that needle-sharing may be due to financial rea-
sons during hard economic times, as the partage of one
syringe between multiple users is less costly. The trans-
mission of HCV is not only associated with contaminated
syringes, but also with the drug preparation equipment,
such cookers and filters, and the water in which the hero-
ine is dissolved (Doerrbecker et al.) [32]. Not surprisingly,
the act of needle-sharing was associated with a higher
HCV-positive status among our cohort, and the χ2 test
yielded significant results (χ2 = 43.22, p = 4.87e-11), leading
us to conclude that the drug users under study who ac-
tively shared their needles were more likely to be HCV-
positive as compared to those that did not.
We next sought to characterize possible serological and
genotypic differences between IDUs and other chronically-
infected patients. The average viral load (IU/mL) was
not significantly different between IDUs and chronically-
infected patients (t = 0.159, df = 109.46, p = 0.4369). Viral
load is a factor routinely taken into account by practitioners
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treatment viral load level has implications for treatment
and is inversely related to treatment response, such that
high viral load is often associated with a poor response to
therapy (Amjad et al.) [33].
Perhaps the most striking difference between our IDU
cohort and the chronically infected patients was their
genotype profile (χ2 = 151.1, df = 5, p = 2.2e-16). The ma-
jority of IDUs harboured the genotypes 1a (60.8%), 3a
(25.6%), while other chronically HCV mono-infected pa-
tients at the Pasteur Institute of Morocco in Casablanca
primarily exhibited genotypes 1b and 2a/2c respectively
(Table 1). A similar IDU profile has been documented in
anti-HCV-positive subjects in other countries, some of
which are in direct contact with Morocco and hugging
the Mediterranean basin, such as Spain, Turkey, Croatia,
and France (Payan et al.; Yildiz et al.; Vince et al.; Lopez-
Labrador et al.) [17,21,34,35]. The Moroccan IDU profile
does not match with neighbouring country Algeria or
central Africa, which exhibit 1b, 2a/2c, and 4 as the pre-
dominant genotypes respectively (Rouabhia et al.; Xu
et al.) [36,37], however we note that these cited studies
were carried out in chronically infected and hemodialysis
patients. One can speculate as to the multiple channels
of heroin trafficking taking place across the Moroccan
borders and the interactions and relationships that con-
tribute to the distinct Moroccan IDU profile. Morocco
shares a border with two neighbouring countries: Algeria
on its Western front and Mauritania to the South. In the
North, one simply crosses the Gibraltar strait to enter
Spain and the European Union. Bordering on the East is
the Atlantic Ocean, however direct access to the Spanish
Canary Islands is possible via direct flights to Gran Canaria
and Tenerife, two very popular touristic destinations.
While the scientific literature lacks data on Mauritania,
Algeria has an anti-HCV positive prevalence estimated at
0.02% (Lavancy; Rouabhia et al.) [36,38]. Interestingly, one
Spanish study on both IDUs and chronically infected
hemodialysis patients revealed that the majority of inject-
ing drug users were genotype 1a (48.5%) (Garcia et al.)
[39]. Finally, two drug user cohorts studied in Lisbon pre-
dominantly exhibited the genotypes 1a and 3a, resulting in
this country harbouring a profile most similar to the local
Moroccan drug users (Almeida Calando et al.) [23]. Col-
lectively, these findings are clues and provide insight into
the possible origin of local circulating genotypes among
the drug users of Morocco. Available published data on
HCV genotypes from IDUs living in countries close in geo-
graphic proximity to Morocco are displayed in Table 2.
Genotyping was performed on 59 out of the 154 IDUs
who had age demographic data available, and patients were
grouped into 7 age intervals (Table 3). At first glance, it
seems that genotype 1a is found in all age groups, while ge-
notypes 3a and 1b were present mostly in younger or olderIDUs respectively. These differing proportions for geno-
types 3a and 1b could be explained by a gradual shift in
genotype profile over time and with older age groups hav-
ing been exposed to different ‘sources’ of HCV as com-
pared to younger generations. Genotype 1b has been found
in the general population and among high-risk groups such
as hemodialysis and blood transfusion patients (Benani
et al.) [25], effectively classifying this genotype as ‘transfu-
sion-related’. Since implementation of the national blood
screening program in 1994 one would expect that younger
subjects would have had a reduced risk of contracting this
genotype, effectively explaining its absence in patients aged
less than 30 years old. The low presence of genotype 4
across all age groups mirrors the lack of genotype 4 in the
general Moroccan population. Authors acknowledge the
insufficient number of subjects in some age intervals, and
further studies with more patients need to be done in order
to accurately assess the uniformity of genotypes in heroin
addicts of all ages.
We next sought to determine if our IDU cohort had a
higher viremia compared between the different geno-
types. ANOVA analysis of genotype and average viremia
(IU/mL)) was significant (F = 2.98, p = 0.0412, n = 49), in-
dicating that individuals infected with genotype 1a had a
higher viral load titer as compared to genotypes 1b, 3a,
and 4a respectively (Figure 2). Our results conflict with a
previous study that did not observe a higher viremia asso-
ciated with genotype 1a across all age groups (Schijman
et al.) [40].
Further complicating the picture is the co-infection with
Hepatitis B virus (HBV) and Human Immunodeficiency
virus (HIV-1), which ultimately alters the natural course
of the disease. It is now well-established that a substan-
tially higher viral load is present in HIV-1 co-infected in-
dividuals as compared to HCV mono-infected patients
(Matthews-Greer et al.; Cribier et al.) [41,42]. HBV/HCV
dual-infection results in cross-suppression of viral replica-
tion, as well as rapid progression of liver disease and
cirrhosis, while HIV-1/HBV co-infected individuals often
exhibit immune suppression and higher viral RNA loads
(Sulkowsky; Filippini) [43,44], mirroring the situation in
HIV-1/HCV co-infected patients. A possible next step is
to address the proportion of HCV-positive Moroccan
IDUs co-infected with either HIV-1 or HBV.
It is widely recognized in the medical community that
different genotypes respond varyingly to antiviral therapy
and that no standard of care (SOC) treatment exists for
all 6 genotypes (Petta & Craxi; Grassi & Aghemo; Esmat
et al.) [45-47], with the ‘gold standard’ treatment currently
being pegylated interferon-α (pegINFα) in combination
with ribavirin (RBV) for 24 to 48 weeks. The addition of
protease inhibitors Boceprevir and Teleprevir imple-
mented in triple therapy significantly increases response
rates and sustained virology response (SVR), however this
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therapy discontinuation (Chopra et al.) [48]. Studies are at
odds in terms of the efficacy of antiviral treatment based
on genotype: genotype 1a has been shown to be negatively
correlated to SVR (Petta & Craxi) [45], while another study
reported a better response rate to dual antiviral therapy in
mono-infected patients using Boceprevir and Telaprevir
(Pelicelli et al.) [49]. Generally speaking, genotype 1b asso-
ciated with a more aggressive disease course, and patients
are more likely to exhibit liver cirrhosis and decompen-
sated liver disease (Zein) [50]. Better response rates are ob-
tained in genotype 2 and genotype 3 patients (about 80%),
while genotype 1-infected patients remain the hardest to
treat overall, reaching an SVR of only about 40% (Jazwinski
& Muir) [51]. With respect to genotype 3 infected individ-
uals, the above mentioned SOC treatment was tailored to
24 weeks and was shown to be effective in terms of SVR,
and further shortened to 12-14 weeks for those patients
exhibiting rapid virologic response (RVR) (Andriulli et al.;
Zeuzem et al.) [52,53]. In light of these findings, the treat-
ment implications for the Moroccan IDU cohort are some-
what positive, seeing that the majority are infected with
either genotypes 1a or 3a. However, the medical commu-
nity must first tackle the issue of treatment refusal before
effective therapy can be implemented, as IDUs have been
known to decline medical help (Mehta et al.) [54]. For it to
be successfully resolved, the issue must be approached on
multiple fronts: reaching out to drug addicts as they are
often marginalized from mainstream society; ensuring that
IDUs are aware of various treatment options at their dis-
posal; undertaking a cost-benefit analysis for each patient
in order to choose the best course of action and a tailored
therapy.Conclusion
This is the first national study on the genotype profile
of Moroccan IDUs living in the northern region of
Morocco, and highlights the fact that they are a distinct
cohort and display different demographic, serologic,
and genotypic profiles. Consequently, IDUs should be
considered apart from the HCV-infected pool derived
from the general population and other high risk groups,
There is brewing hope for worldwide HCV elimination,
with the strategy using a ‘cocktail’ consisting of trans-
mission prevention, genotype-tailored treatments, routine
blood-product screening, and vaccine development (Hegan
& Schinazi) [55]. Moroccan health authorities must imple-
ment public health campaigns to address this issue of high
seroprevalence in IDUs, as well as using prevention as their
primary tactic for disease control. Finally, combatting the
HCV epidemic entails a joint effort between health practi-
tioners and local governments, employing a continuous
epidemiological surveillance.Materials and methods
Patient recruitment and selection criteria
This research is a retrospective study and a collaborative
effort between the Hasnouna Center for Addictology in
Tangier and the Pasteur Institute of Morocco in Casa-
blanca between the years 2011 to 2013. All subjects in-
cluded in the study fall into two distinct categories:
registered IDU patients at the Hasnouna Center who are
currently undergoing detoxification and/or therapy for
their drug (heroin) habit and are on methadone treatment,
or chronic HBV carriers that are being treated with anti-
viral therapy at the Pasteur Institute of Morocco. Drug ad-
dict patients all had an ‘active’ drug addiction and were
presumed to be representative of the general intravenous
drug user population in Morocco, thereby serving as a
source of data extrapolation. Prior to enrolment of sub-
jects, an internal ethics committee at the Pasteur Institute
reviewed the study and approved it as a human subject
study that did not violate or harm subjects in any way.
IDU patients were first recruited and evaluated by two at-
tending physicians at the Hasnouna Center, during which
the objectives of the study were explained to each patient
by the attending physicians, and no undue coercion was
exercised if the patient refused to participate. There were
no minors recruited and each patient signed an informed
consent form demonstrating his or her willingness to par-
ticipate in the study. After which, a follow-up visit was
scheduled during which: blood was drawn, data for the
various variables was collected, and treatment was initi-
ated (methadone). Patient blood samples which tested
positive for anti-HCV antibodies were frozen in sterile
bags and sent to the Molecular Biology Laboratory at the
Pasteur Institute of Morocco for viral RNA detection, viral
load quantification, and genotyping. Chronically-infected
HCV patients (non-IDUs) who were used as the compara-
tor population are currently having their regular blood
tests done at the Pasteur Institute of Morocco. All subjects
have signed an informed consent form in which they
allowed their personal data and lab results to be used for
any research purposes.
Samples
Blood sera from 211 IDU patients were collected at the
Hasnouna Addiction Center in Tangier from 2011 to
2013, aliquoted (EDTA) and stored at -20 C until further
use. Blood sera (n = 151) from chronically infected pa-
tients were collected at the Pasteur Institute of Morocco
in 2013, aliquoted (EDTA), and stored at -20 C until fur-
ther use.
RNA detection and genotyping
Viral RNA extraction was done using COBAS Ampliprep™;
viral load quantification was performed using real-time
RT-PCR 48 HCV test (Cobas Ampliprep/Cobas TaqMan™
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limit of detection of 15 IU/mL, all samples above this limit
were considered HCV positive; Viral RNA was reverse
transcribed and amplified with Versant HCV Amplifica-
tion 2.0 kit (LiPA) (using 26 μL of amplification mix, 4 μL
of enzyme mix, 20 μL of viral RNA) and using GeneAmp
PCR System 9700 (Applied Biosystems, Life Technologies,
USA). Viral samples were genotyped using Versant HCV
Genotype Assay version 2.0 (Siemens). All tests were per-
formed according to the manufacturer’s instructions.
Statistical analyses
All data was analyzed using statistical software R (ver-
sion 3.0.1): χ2, ANOVA, independent sample T-test, and
Pearson’s Correlation. For all tests, all p values less than
0.05 were considered statistically significant.
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